Effect of Potent P2Y₁₂ Inhibitors on Ventricular Arrhythmias and Cardiac Dysfunction in Coronary Artery Disease: A Systematic Review and Meta-Analysis

Table 3

Outcomes of the potent inhibitors.

Study	Heart failure		Cardiogenic Shock		Ventricular tachycardia		Ventricular fibrillation
	Potent inhibitors	Clopidogrel	Potent inhibitors	Clopidogrel	Potent inhibitors	Clopidogrel	Potent inhibitors	Clopidogrel
DISPERSE-2 [11]	N/A	N/A	N/A	N/A	166/663	93/327	N/A	N/A
PLATO [1, 18]	196/9333	198/9291	60/9333	66/9291	29/9333	33/9291	48/9333	64/9291
PHILO [12, 19]	11/387	13/380	N/A	N/A	8/387	8/380	3/387	1/380
JUMBO-TIMI26 [13, 20]	1/651	0/254	N/A	N/A	N/A	N/A	N/A	N/A
TRITON-TIMI 38 [2, 21]	71/6741	92/6716	13/6741	8/6716	24/6741	25/6716	18/6741	25/6716
Ge et al. [14, 22]	2/463	4/229	4/463	2/229	3/463	1/229	1/463	0/229
TRILOGY ACS [15, 23]	199/4623	238/4617	15/4623	23/4617	15/4623	20/4617	3/4623	15/4617
TRIGGER PCI [16, 24]	1/210	5/210	N/A	N/A	0/210	1/210	0/210	0/210
ETAMI [17]	N/A	N/A	1/31	2/31	N/A	N/A	N/A	N/A

Values are n/N
N/A: not available, DISPERSE-2: dose confirmation study assessing anti-platelet effects of AZD6140 vs. clopidogrel in non-ST-segment elevation myocardial infarction-2, PLATO: platelet inhibition and patient outcomes, PHILO: ticagrelor vs. clopidogrel in Japanese, Korean, and Taiwanese patients with acute coronary syndrome, JUMBO-TIMI26: joint utilization of medications to block platelets optimally-thrombolysis in myocardial infarction 26, TRITON-TIMI 38: trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel–thrombolysis in myocardial infarction, TRILOGY ACS: the targeted platelet inhibition to clarify the optimal strategy to medically manage acute coronary syndromes, TRIGGER PCI: testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel, ETAMI: early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction.
Heart failure was defined as any reported congestive heart failure, acute and chronic heart failure.
†Ventricular tachycardia (VT) was categorized into sustained VT (lasting >30 s), non-sustained ventricular tachycardia (NSVT) (≥4 beats and <30 s in length), and triplets (3 ventricular beats).